Early detection of prostate cancer increases chances of patients' survival. Our automated non-invasive system for computer-aided diagnosis (CAD) of prostate cancer segments the prostate on diffusion-weighted magnetic resonance images (DW-MRI) acquired at different b-values, estimates its apparent diffusion coefficients (ADC), and classifies their descriptors - empirical cumulative distribution functions (CDF) - with a trained deep learning network. To segment the prostate, an evolving geometric (level-set-based) deformable model is guided by a speed function depending on intensity attributes extracted from the DW-MRI with nonnegative matrix factorization (NMF). For a more robust evolution, the attributes are fused with a probabilistic shape prior and estimated spatial dependencies between prostate voxels. To preserve continuity, the ADCs of the segmented prostate volume at different b-values are normalized and refined using a generalized Gauss-Markov random field image model. The CDFs of the refined ADCs at different b-values are considered global water diffusion features and used to distinguish between benign and malignant prostates. A deep learning network of stacked non-negativity-constrained auto-encoders (SNCAE) is trained to classify the benign or malignant prostates on the basis of the constructed CDFs. Our experiments on 53 clinical DW-MRI data sets resulted in 92.3% accuracy, 83.3% sensitivity, and 100% specificity, indicating that the proposed CAD system could be used as a reliable non-invasive diagnostic tool.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.compbiomed.2016.12.010 | DOI Listing |
Medicine (Baltimore)
January 2025
Urology and Metabolic Rehabilitation Center, Beijing Rehabilitation Hospital, Capital Medical University, Xixia Zhuang, Badachu, Shijingshan District, Beijing, China.
Prostate cancer is epithelial malignant prostate hyperplasia caused by a tumor. We found prostate cancer GSE141551 and GSE200879 profiles from gene expression omnibus database, followed by differentially expressed genes (DEGs) analysis, weighted gene co-expression network analysis, protein-protein interaction analysis, gene function enrichment analysis, and comparative toxicology database analysis. Finally, the gene expression heat map was drawn, and miRNA information regulating core DEGs was retrieved.
View Article and Find Full Text PDFJ Med Internet Res
January 2025
Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, US.
Background: Most cancer survivors have multiple cardiovascular risk factors, increasing their risk of poor cardiovascular and cancer outcomes. The Automated Heart-Health Assessment (AH-HA) tool is a novel electronic health record clinical decision support tool based on the American Heart Association's Life's Simple 7 cardiovascular health (CVH) metrics to promote CVH assessment and discussion in outpatient oncology. Before proceeding to future implementation trials, it is critical to establish the acceptability of the tool among providers and survivors.
View Article and Find Full Text PDFAm J Health Promot
January 2025
College of Social Work, University of South Carolina, Columbia, SC, USA.
Purpose: Artificially Intelligent (AI) chatbots have the potential to produce information to support shared prostate cancer (PrCA) decision-making. Therefore, our purpose was to evaluate and compare the accuracy, completeness, readability, and credibility of responses from standard and advanced versions of popular chatbots: ChatGPT-3.5, ChatGPT-4.
View Article and Find Full Text PDFJ Med Chem
January 2025
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211100, P. R. China.
Molecular glue degraders induce "undruggable" protein degradation by a proximity-induced effect. Inspired by the clinical success of immunomodulatory drugs, we aimed to design novel molecular glue degraders targeting GSPT1. Here, we report the design of a series of GSPT1 molecular glue degraders.
View Article and Find Full Text PDFProstate
January 2025
Department of Urology, Weill Cornell Medicine, New York City, New York, USA.
Purpose: Actinium-225 labeled prostate-specific membrane antigen (PSMA) targeted radionuclide therapy has emerged as a potential treatment option in the management of men with metastatic castrate-resistant prostate cancer (mCRPC). This study investigated molecular imaging-derived parameters and compared imaging response of lesions categorized by tumor site.
Methods: Men with mCRPC treated with [225Ac]Ac-J591 from 2017 to 2022 at our center on two prospective trials (NCT03276572 and NCT04506567) with pre- and post-treatment [68Ga]Ga-PSMA-11 Positron Emission Tomography (PET) imaging studies available were included.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!